Founded in 1873 and headquartered in Zofingen, Switzerland, Siegfried Holding AG operates as a leading CDMO for both small biotech firms and large pharmaceutical companies. The company's business is divided into two main segments: Drug Substances, which includes custom and generic APIs and intermediates, and Drug Products, which covers oral solids, sterile injectables, ophthalmics, and inhalation products. Siegfried's capabilities include complex chemistry, exclusive synthesis, and advanced formulation technologies, supported by a global footprint of over a dozen production facilities across three continents. In recent years, the company has expanded its technological capabilities into emerging areas such as viral vectors and cell and gene therapies through strategic acquisitions like DINAMIQS. By offering end-to-end services from pilot manufacturing to commercial production, Siegfried acts as a critical supply chain partner for highly regulated pharmaceutical manufacturing.
